Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Nov;50(4):833-836.
doi: 10.1007/s11239-020-02244-y.

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

Chiara Kessler  1 , Hans Stricker  2 , Daniela Demundo  3 , Luigia Elzi  4 , Rita Monotti  5 , Giorgia Bianchi  6 , Michael Llamas  7 , Luca Spinedi  2 , Davide Rossi  1 , Alessandro Felice Chiesa  7 , Alberto Pagnamenta  7 , Marco Conti  7 , Gabriele Casso  8 , Elisa Stoira  5 , Elisa Valenti  7 , Giuseppe Colucci  9 , Georg Stussi  1 , Bernhard Gerber  10 , Marco Previsdomini  7
Affiliations
Observational Study

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

Chiara Kessler et al. J Thromb Thrombolysis. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

D. Rossi reports grants and personal fees from Abbvie, grants and personal fees from Janssen, grants and personal fees from Gilead, grants and personal fees from AstraZeneca, personal fees from Verastem, personal fees from Loxo, grants from Cellestia, during the conduct of the study; B. Gerber reports grants and personal fees from Pfizer; personal fees and funding for accredited continuing medical education from Sanofi and Alnylam, during the conduct of the study, funding for accredited continuing medical education program from Axonlab, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Janssen, Mitsubishi Tanabe Pharma, NovoNordisk, Octapharma, Takeda, Sanofi, SOBI; non-financial support from Axonlab and Thermo Fisher from outside the submitted work; All other authors report no conflict of interest related to this study.

References

    1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 doi: 10.1182/blood.2020006000. - DOI - PMC - PubMed
    1. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi: 10.1016/S2352-3026(20)30145-9. - DOI - PMC - PubMed
    1. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424. doi: 10.1111/jth.14830. - DOI - PMC - PubMed
    1. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020 doi: 10.1111/jth.14888. - DOI - PMC - PubMed
    1. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quere I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 doi: 10.1016/j.jacc.2020.04.031. - DOI - PMC - PubMed

MeSH terms